More on PPIs and Cdiff risk

Another retrospective analysis of patients on acid suppression (H2-PPIs-both) found they had 2.5 times the risk of complications, and almost 5 times the risk of death with Cdiff, compared to those not on these medications (abstract). As such, the FDA has now issued a MedSafety warning on the risk, and advocating using the lowest dose for the shortest time possible (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment